NewGenIvf Group Limited
NIVFHealthcareNASDAQMedical Care Facilities
Scan Results
Daily timeframeNewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and. At a $4.3M market cap, NewGenIvf Group Limited ranks as a micro-cap company within healthcare. The company provides a range of fertility treatment solutions, including in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening, hysteroscopy, sperm analysis, sorting, washing, and freezing, and egg freezing.
Market Cap
$4.3M
Beta
-0.04
P/E (TTM)
0.01
P/E (Fwd)
0.05
EPS (TTM)
$107.76
EPS (Fwd)
$28.02
ROE
79.4%
ROA
-36.9%
Cash
$958,556
Total Debt
$4.9M
Free CF
-$10.5M
52W Change
-99.8%
Annual Financials
Cash vs Debt
Where NIVF stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, NIVF finished 87.04% below its 150-day moving average ($11.03) and 97.38% below its 200-day moving average ($54.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NIVF overbought or oversold?
At the July 15, 2026 close, NIVF's RSI(14) was 28.5, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, NIVF has $959K in cash with $4.9M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$10.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 79.4%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $5.9M (2022) to $4.7M (2025), a 20% decline worth watching.
With a beta below 0.7, NewGenIvf Group Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. NewGenIvf Group Limited carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence NewGenIvf Group Limited's trajectory.